Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
礼来（NYSE:LLY）周一同意以每股现金57美元的价格收购morphic holding inc（NASDAQ：MORF），总价约32亿美元。
Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic是一家生物制药公司，致力于开发一系列口服整合素治疗慢性疾病的药物组合，包括自身免疫性、心血管和代谢性疾病、纤维化和癌症。
Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform.
Morphic还在使用其专有的MInt技术平台与Schrödinger合作，推进其队列和发现活动。
Morphic's lead program, MORF-057, is a selective oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD) that can potentially improve outcomes and expand treatment options for patients.
Morphic的主导项目MORF-057是一种选择性的口服小分子α4β7整合素抑制剂，用于治疗炎症性肠病（IBD），可能改善患者的治疗效果并扩大治疗选择。
MORF-057 is being evaluated in two Phase 2 studies in ulcerative colitis and one Phase 2 study in Crohn's disease.
MORF-057正在两项溃疡性结肠炎的2期研究和一项克罗恩病的2期研究中进行评估。
In its first quarter 2024 earnings release, Morphic said enrollment continues on track for the EMERALD-2 global phase 2b trial of MORF-057 in patients with moderate-to-severe ulcerative colitis.
在其2024年第一季度业绩发布中，Morphic表示，目前EMERALD-2全球第20亿阶段的MORF-057治疗中度至重度溃疡性结肠炎患者的招募工作正在按计划进行。
The primary endpoint of EMERALD-2 is the clinical remission rate at 12 weeks, and it is expected to be reported in the first half of 2025.
EMERALD-2的主要终点评价是12周时的临床缓解率，预计将在2025年上半年公布。
Additionally, Morphic is developing a preclinical pipeline of other molecules for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer.
此外，Morphic正在开发一条针对自身免疫性疾病、肺动脉高压病、纤维化疾病和癌症的临床前药物管线。
"Morphic has always believed that the immense potential of MORF-057 to benefit patients suffering from IBD could be optimized by the ideal strategic partner. Lilly brings unparalleled resources and commitment to the inflammation and immunology field," commented Praveen Tipirneni, CEO of Morphic Therapeutic. "We built the Morphic Integrin Technology platform to realize the vast opportunity of integrin therapeutics."
Morphic Therapeutic的首席执行官Praveen Tipirneni评论说:"morphic一直相信，morf-057对受炎症和免疫领域的患者产生巨大影响的潜力可以通过最理想的战略合作伙伴得到优化。Lilly为炎症和免疫领域带来了无与伦比的资源和承诺。我们构建了morphic integrin technology平台，以实现整合素治疗的广阔机遇。"
The transaction is expected to close in the third quarter of 2024. The purchase price payable at closing represents a premium of approximately 79.0% to the closing stock price on July 5, 2024, and 87.2% to the 30-day volume-weighted average trading price of Morphic's common stock ended on July 5, 2024, the last trading day before the announcement of the transaction.
交易预计将在2024年第三季度完成。收购价格将在交易完成时支付，较2024年7月5日收盘股价溢价约79.0%，较Morphic普通股30天成交量加权平均交易价于2024年7月5日结束时的价格溢价87.2%。
Price Action: MORF shares are up 75.4% at $55.84, and LLY shares are up 0.58% at $919.88 during the premarket session at last check Monday.
价格行动：在周一的前场交易中，MORF股价上涨75.4%，至55.84美元，LLY股价上涨0.58%，至919.88美元。
Photo by rafapress on Shutterstock
rafaress的shutterstock照片
- GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds.
- 研究发现，Wegvoy、Mounjaro等GLP-1治疗能够降低肥胖相关癌症的风险。